← Jiangsu Hengrui Medicine overview

Jiangsu Hengrui Medicine vs Xizang Haisco Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Jiangsu Hengrui Medicine Co Ltd (600276.CG)

Q3 2026
▲4▼1

Hengrui's innovative drug shift, deals, buyback drive Q3

  • Innovative drugs surpass 60% of revenue Hengrui's innovative drugs exceeded 60% of total revenue in Q3, driving profit growth even as overall sales dipped slightly. This shift toward higher-margin medicines is key to future earnings.

    This is the core driver of profit growth and strategic transformation in Q3.

  • Positive Phase 3 results for oral GLP-1 Hengrui reported positive Phase 3 results for its oral GLP-1 drug HRS-7535, a potential treatment for diabetes and obesity. This could open a large new market and boost future revenue.

    This is a major pipeline milestone that could drive future growth.

  • Major licensing deals and FDA orphan drug status Hengrui signed licensing deals with Bristol Myers and Merck, and received FDA orphan drug status for a rare disease drug. These partnerships validate its research and bring in upfront payments.

    These deals provide external validation and near-term cash, supporting valuation.

  • 1–2bn yuan buyback signals confidence Hengrui announced a 1–2 billion yuan share buyback, signaling management's confidence in the company's future and supporting the stock price.

    Buybacks can boost investor confidence and support share price.

  • Competition in children's myopia market Qilu's atropine application for children's myopia could pressure sales of Hengrui's Shengdi. This competitive threat may limit growth in that segment.

    This is a key counterweight that could hurt sales and market share.

August 2026
▲4

Hengrui's pipeline and buyback drive value as China biotech gains

  • China's drug development rise boosts Hengrui's licensing appeal China has overtaken the US in clinical drug development, with a third of Big Pharma's licensed drugs now from Chinese labs. Hengrui's $15.2bn Bristol Myers and $2bn Merck deals show its pipeline is in demand, supporting future revenue and share price.

    This structural shift increases demand for Hengrui's drug candidates and validates its licensing business model.

  • Buyback and employee plan signal confidence Hengrui will spend 1-2 billion yuan buying back A-shares for an employee stock ownership plan. This reduces shares outstanding and shows management believes the stock is undervalued, which can lift the price.

    Buybacks directly affect capital structure and signal insider confidence, a key driver for the stock.

  • Interim results show innovative drug growth First-half revenue fell 1.94% to 15.46bn yuan, but net profit rose 0.34% and innovative drug sales jumped 16.38%, now 63% of drug sales. Non-oncology innovative drugs surged 74%, showing a successful shift to higher-value medicines.

    The earnings report reveals the core profit driver—innovative drugs—which is key to the investment case.

  • Oral GLP-1 application accepted, opening huge market China's regulator accepted Hengrui's marketing application for HRS-7535, an oral GLP-1 for diabetes and weight loss. Positive Phase III results support approval, potentially tapping the fast-growing obesity and diabetes market.

    This is a concrete pipeline milestone that could add a major new revenue stream, directly impacting future earnings.

Latest
▲4

Hengrui's pipeline and buyback drive value as China biotech gains

  • China's drug development rise boosts Hengrui's licensing appeal China has overtaken the US in clinical drug development, with a third of Big Pharma's licensed drugs now from Chinese labs. Hengrui's $15.2bn Bristol Myers and $2bn Merck deals show its pipeline is in demand, supporting future revenue and share price.

    This structural shift increases demand for Hengrui's drug candidates and validates its licensing business model.

  • Buyback and employee plan signal confidence Hengrui will spend 1-2 billion yuan buying back A-shares for an employee stock ownership plan. This reduces shares outstanding and shows management believes the stock is undervalued, which can lift the price.

    Buybacks directly affect capital structure and signal insider confidence, a key driver for the stock.

  • Interim results show innovative drug growth First-half revenue fell 1.94% to 15.46bn yuan, but net profit rose 0.34% and innovative drug sales jumped 16.38%, now 63% of drug sales. Non-oncology innovative drugs surged 74%, showing a successful shift to higher-value medicines.

    The earnings report reveals the core profit driver—innovative drugs—which is key to the investment case.

  • Oral GLP-1 application accepted, opening huge market China's regulator accepted Hengrui's marketing application for HRS-7535, an oral GLP-1 for diabetes and weight loss. Positive Phase III results support approval, potentially tapping the fast-growing obesity and diabetes market.

    This is a concrete pipeline milestone that could add a major new revenue stream, directly impacting future earnings.

July 2026
▲3▼1

Hengrui's innovative drug pipeline and global deals drive growth

  • Innovative drugs now over 60% of revenue Hengrui's innovative drug sales exceeded 60% of total revenue for the first time, showing strong demand. This shift from traditional generics to higher-margin innovative drugs supports profit growth and a higher valuation.

    This milestone shows the company's successful transformation and is a key driver of its earnings and stock price.

  • Positive Phase 3 results for oral GLP-1 drug Kailera reported positive Phase 3 results for the oral GLP-1 drug HRS-7535, which Hengrui developed. This validates Hengrui's pipeline and opens a large market for obesity and diabetes, boosting future revenue potential.

    This is a major clinical milestone that de-risks a high-value asset and could lead to significant future sales.

  • New drug approvals and orphan drug designation Hengrui received clinical trial approval for HRS-8797 for atopic dermatitis, FDA orphan drug designation for SHR-4375 for pancreatic cancer, and approval for insulin degludec, China's first long-acting insulin analogue. These expand its product portfolio and market reach.

    These regulatory wins add new growth drivers and demonstrate Hengrui's R&D strength across multiple therapeutic areas.

  • Competition intensifies in children's myopia drug market Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding competition for Hengrui's subsidiary Shengdi, which has a similar product in marketing application. This could pressure future sales and market share.

    This is a real counterweight that could limit upside in one of Hengrui's near-term opportunities.

▲3▼1

Hengrui's innovative drug pipeline and global deals drive growth

  • Innovative drugs now over 60% of revenue Hengrui's innovative drug sales exceeded 60% of total revenue for the first time, showing strong demand. This shift from traditional generics to higher-margin innovative drugs supports profit growth and a higher valuation.

    This milestone shows the company's successful transformation and is a key driver of its earnings and stock price.

  • Positive Phase 3 results for oral GLP-1 drug Kailera reported positive Phase 3 results for the oral GLP-1 drug HRS-7535, which Hengrui developed. This validates Hengrui's pipeline and opens a large market for obesity and diabetes, boosting future revenue potential.

    This is a major clinical milestone that de-risks a high-value asset and could lead to significant future sales.

  • New drug approvals and orphan drug designation Hengrui received clinical trial approval for HRS-8797 for atopic dermatitis, FDA orphan drug designation for SHR-4375 for pancreatic cancer, and approval for insulin degludec, China's first long-acting insulin analogue. These expand its product portfolio and market reach.

    These regulatory wins add new growth drivers and demonstrate Hengrui's R&D strength across multiple therapeutic areas.

  • Competition intensifies in children's myopia drug market Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding competition for Hengrui's subsidiary Shengdi, which has a similar product in marketing application. This could pressure future sales and market share.

    This is a real counterweight that could limit upside in one of Hengrui's near-term opportunities.

Xizang Haisco Pharmaceutical Group Co Ltd (002653.CS)

Q3 2026
▲4

Haisco's profit surge and new licensing deals drive gains

  • First-half profit forecast up over 500% Haisco expects first-half net profit to rise 513% to 575% year-on-year, driven by rapid innovative drug sales and upfront payments from out-licensing deals. This signals strong earnings momentum and boosts investor confidence in the stock.

    This is the core earnings catalyst that directly explains the stock's positive momentum.

  • New pain drug HSK51155 gets clinical trial approval Haisco's self-developed oral pain drug HSK51155 received clinical trial approval in China. It is part of a global partnership with AbbVie worth over $700 million, validating Haisco's research capabilities and adding a potential future revenue stream.

    This pipeline advancement supports long-term growth prospects and reinforces the value of Haisco's licensing strategy.

  • New autoimmune licensing deal with Sentivera Haisco licensed a preclinical autoimmune asset to US-based Sentivera for $75.89 million upfront (cash plus equity), up to $1.46 billion in milestones, and royalties. This brings immediate cash and validates Haisco's drug discovery platform.

    This is a fresh, material deal that directly adds near-term cash and potential long-term value.

  • Sentivera launch highlights China biotech out-licensing trend Sentivera, backed by Metsera investors, licensed Haisco's immunology asset, with total deal value potentially exceeding $1.5 billion. This NewCo model is gaining traction, boosting Haisco's reputation and future deal-making potential.

    It underscores the growing demand for Chinese biotech assets and Haisco's ability to secure favorable terms.

August 2026
▲4

Haisco's profit surge and new licensing deals drive gains

  • First-half profit forecast up over 500% Haisco expects first-half net profit to rise 513% to 575% year-on-year, driven by rapid innovative drug sales and upfront payments from out-licensing deals. This signals strong earnings momentum and boosts investor confidence in the stock.

    This is the core earnings catalyst that directly explains the stock's positive momentum.

  • New pain drug HSK51155 gets clinical trial approval Haisco's self-developed oral pain drug HSK51155 received clinical trial approval in China. It is part of a global partnership with AbbVie worth over $700 million, validating Haisco's research capabilities and adding a potential future revenue stream.

    This pipeline advancement supports long-term growth prospects and reinforces the value of Haisco's licensing strategy.

  • New autoimmune licensing deal with Sentivera Haisco licensed a preclinical autoimmune asset to US-based Sentivera for $75.89 million upfront (cash plus equity), up to $1.46 billion in milestones, and royalties. This brings immediate cash and validates Haisco's drug discovery platform.

    This is a fresh, material deal that directly adds near-term cash and potential long-term value.

  • Sentivera launch highlights China biotech out-licensing trend Sentivera, backed by Metsera investors, licensed Haisco's immunology asset, with total deal value potentially exceeding $1.5 billion. This NewCo model is gaining traction, boosting Haisco's reputation and future deal-making potential.

    It underscores the growing demand for Chinese biotech assets and Haisco's ability to secure favorable terms.

Latest
▲4

Haisco's profit surge and new licensing deals drive gains

  • First-half profit forecast up over 500% Haisco expects first-half net profit to rise 513% to 575% year-on-year, driven by rapid innovative drug sales and upfront payments from out-licensing deals. This signals strong earnings momentum and boosts investor confidence in the stock.

    This is the core earnings catalyst that directly explains the stock's positive momentum.

  • New pain drug HSK51155 gets clinical trial approval Haisco's self-developed oral pain drug HSK51155 received clinical trial approval in China. It is part of a global partnership with AbbVie worth over $700 million, validating Haisco's research capabilities and adding a potential future revenue stream.

    This pipeline advancement supports long-term growth prospects and reinforces the value of Haisco's licensing strategy.

  • New autoimmune licensing deal with Sentivera Haisco licensed a preclinical autoimmune asset to US-based Sentivera for $75.89 million upfront (cash plus equity), up to $1.46 billion in milestones, and royalties. This brings immediate cash and validates Haisco's drug discovery platform.

    This is a fresh, material deal that directly adds near-term cash and potential long-term value.

  • Sentivera launch highlights China biotech out-licensing trend Sentivera, backed by Metsera investors, licensed Haisco's immunology asset, with total deal value potentially exceeding $1.5 billion. This NewCo model is gaining traction, boosting Haisco's reputation and future deal-making potential.

    It underscores the growing demand for Chinese biotech assets and Haisco's ability to secure favorable terms.

© 2026 MarketDXWhy